What is William Blair’s Estimate for KZR FY2024 Earnings?

Kezar Life Sciences, Inc. (NASDAQ:KZR) – Investment analysts at William Blair upped their FY2024 EPS estimates for Kezar Life Sciences in a research report issued to clients and investors on Wednesday, November 13th. William Blair analyst M. Phipps now anticipates that the company will earn ($2.06) per share for the year, up from their previous estimate of ($12.50). William Blair has a “Market Perform” rating on the stock. The consensus estimate for Kezar Life Sciences’ current full-year earnings is ($6.47) per share. William Blair also issued estimates for Kezar Life Sciences’ Q4 2024 earnings at ($2.81) EPS, Q1 2025 earnings at ($2.73) EPS, Q2 2025 earnings at ($2.75) EPS, Q3 2025 earnings at ($2.78) EPS, Q4 2025 earnings at ($2.80) EPS, FY2025 earnings at ($11.06) EPS, FY2026 earnings at ($11.86) EPS and FY2027 earnings at ($12.84) EPS.

Kezar Life Sciences (NASDAQ:KZR) last issued its earnings results on Tuesday, November 12th. The company reported ($2.78) earnings per share (EPS) for the quarter, beating the consensus estimate of ($3.03) by $0.25.

KZR has been the subject of a number of other reports. HC Wainwright reaffirmed a “neutral” rating on shares of Kezar Life Sciences in a research report on Monday, October 14th. Wells Fargo & Company reduced their target price on shares of Kezar Life Sciences from $20.00 to $11.00 and set an “equal weight” rating for the company in a report on Thursday.

Kezar Life Sciences Stock Performance

Shares of NASDAQ KZR opened at $7.46 on Monday. The company has a current ratio of 7.65, a quick ratio of 9.58 and a debt-to-equity ratio of 0.05. The company has a market capitalization of $54.46 million, a P/E ratio of -0.57 and a beta of 0.22. Kezar Life Sciences has a 12 month low of $5.20 and a 12 month high of $11.35. The stock has a 50 day moving average of $7.20 and a 200-day moving average of $6.82.

Institutional Investors Weigh In On Kezar Life Sciences

A number of institutional investors have recently modified their holdings of the business. Stonepine Capital Management LLC acquired a new stake in Kezar Life Sciences in the 2nd quarter worth about $630,000. BNP Paribas Financial Markets boosted its stake in shares of Kezar Life Sciences by 35.4% in the first quarter. BNP Paribas Financial Markets now owns 273,430 shares of the company’s stock valued at $247,000 after buying an additional 71,543 shares during the period. Vanguard Group Inc. grew its position in Kezar Life Sciences by 1.0% during the first quarter. Vanguard Group Inc. now owns 3,094,224 shares of the company’s stock worth $2,790,000 after buying an additional 30,740 shares in the last quarter. Acadian Asset Management LLC increased its stake in Kezar Life Sciences by 42.5% during the 1st quarter. Acadian Asset Management LLC now owns 1,790,838 shares of the company’s stock worth $1,613,000 after acquiring an additional 534,203 shares during the period. Finally, Point72 Asia Singapore Pte. Ltd. acquired a new position in Kezar Life Sciences in the 2nd quarter valued at $63,000. Institutional investors own 67.90% of the company’s stock.

About Kezar Life Sciences

Kezar Life Sciences, Inc, a clinical-stage biotechnology company, engages in the discovery and development of novel small molecule therapeutics to treat unmet needs in immune-mediated diseases and cancer in the United States. The company's lead product candidate is zetomipzomib (KZR-616), a selective immunoproteasome inhibitor that is in Phase 2b clinical trials for various indications, including lupus nephritis, dermatomyositis, and polymyositis; Phase 1b clinical trials in systemic lupus erythematosus; and completed Phase 2a clinical trials in lupus nephritis.